Lyell Immunopharma (LYEL) Liabilities and Shareholders Equity (2020 - 2026)

Lyell Immunopharma has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $350.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 18.42% year-over-year to $350.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 32.36% YoY) and the FY2025 annual result came in at $340.1 million, down 30.72% from the prior year.
• Liabilities and Shareholders Equity grew to $350.6 million in Q1 2026 per LYEL's latest filing, from $340.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.1 billion in Q1 2022 and troughed at $340.1 million in Q4 2025.
• A 5-year average of $684.8 million and a median of $694.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity retreated 16.84% in 2022, then slumped 41.08% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $937.6 million in 2022, then declined by 20.0% to $750.0 million in 2023, then sank by 34.55% to $490.9 million in 2024, then slumped by 30.72% to $340.1 million in 2025, then rose by 3.11% to $350.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $350.6 million, $340.1 million, and $408.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.